Topline:
The FDA's recent approval of iloprost (Aurlumyn) for severe frostbite marks a groundbreaking advancement, offering hope to patients facing potential amputation of fingers or toes. This first-ever treatment option not only heralds a significant shift in frostbite management but also equips healthcare providers with an effective tool in their therapeutic arsenal.



